Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors

Cells
Roberto AgrestiFrancesca Bianchi

Abstract

Wound healing fluid that originates from breast surgery increases the aggressiveness of cancer cells that remain after the surgery. We determined the effects of the extent of surgery and tumor-driven remodeling of the surrounding microenvironment on the ability of wound-healing to promote breast cancer progression. In our analysis of a panel of 34 cytokines, chemokines, and growth factors in wound healing fluid, obtained from 27 breast carcinoma patients after surgery, the levels of several small molecules were associated with the extent of cellular damage that was induced by surgery. In addition, the composition of the resulting wound healing fluid was associated with molecular features of the removed tumor. Specifically, IP-10, IL-6, G-CSF, osteopontin, MIP-1a, MIP-1b, and MCP1-MCAF were higher in more aggressive tumors. Altogether, our findings indicate that the release of factors that are induced by removal of the primary tumor and subsequent wound healing is influenced by the extent of damage due to surgery and the reactive stroma that is derived from the continuously evolving network of interactions between neoplastic cells and the microenvironment, based on the molecular characteristics of breast carcinoma cells.

References

Jul 5, 2003·Physiological Reviews·Sabine Werner, Richard Grose
Aug 23, 2003·Lancet·Elda TagliabueSylvie Ménard
Feb 13, 2004·World Journal of Surgery·Diana Vilar-ComptePatricia Volkow
Apr 21, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elda TagliabueSylvie Ménard
Nov 27, 2007·Nature Clinical Practice. Oncology·Romano DemicheliMichael Baum
May 3, 2008·European Journal of Clinical Investigation·X WangJ Sun
Oct 3, 2009·Journal of Cell Communication and Signaling·Susan Amanda LundMarta Scatena
Apr 8, 2011·Current Pharmaceutical Biotechnology·M J CarliniL Puricelli
Nov 1, 2011·Immunity·Ali KuraishySergei I Grivennikov
Dec 6, 2011·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Takeshi ImamuraYasumichi Inoue
Feb 22, 2012·The Journal of Cell Biology·Pengfei LuZena Werb
Aug 1, 2012·Oncology Letters·Mingli LiuJonathan K Stiles
Nov 20, 2012·Indian Journal of Plastic Surgery : Official Publication of the Association of Plastic Surgeons of India·Jumaat Mohd Yussof ShahSuneet Sood
Aug 21, 2013·Critical Reviews in Oncology/hematology·Wim CeelenMarc Mareel
Aug 29, 2013·Plastic Surgery International·Hani Sinno, Satya Prakash
Jul 19, 2014·Cancer Research·Sabina SangalettiClaudia Chiodoni
Feb 13, 2015·Cancer Growth and Metastasis·Kimberly M ArnoldJennifer Sims-Mourtada
Feb 26, 2015·Journal of Cellular Physiology·Francesca BianchiManuela Campiglio
Dec 1, 2012·The Journal of the American College of Clinical Wound Specialists·Kristin Anderson, Rose L Hamm
Aug 16, 2016·Breast Cancer Research : BCR·Karen M BussardFrank C Marini
Sep 15, 2016·Oncotarget·Federica TurdoManuela Campiglio
Aug 16, 2017·Molecular Cancer·Alberto OcanaArnoud J Templeton
Mar 4, 2018·Cell Death & Disease·Hailin ZhaoDaqing Ma

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
biopsy

Software Mentioned

Image Pro - Plus
SAS
GraphPad
GraphPad Prism

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.